Back to today’s briefing

Story perspectives

Inflammatix Gains FDA Nod for Revolutionary Infection Test

1/22/2025

49 8

Summary

Story summary

Inflammatix has achieved a significant milestone with FDA marketing authorization for its TriVerity test, a groundbreaking rapid diagnostic tool. By analyzing 29 immune response genes, this test swiftly identifies infections and predicts severe illness, revolutionizing patient triage and enhancing outcomes in emergency departments. A leap forward in healthcare innovation!

1 of 1

Story summary

Inflammatix has achieved a significant milestone with FDA marketing authorization for its TriVerity test, a groundbreaking rapid diagnostic tool. By analyzing 29 immune response genes, this test swiftly identifies infections and predicts severe illness, revolutionizing patient triage and enhancing outcomes in emergency departments. A leap forward in healthcare innovation!